advancing medical research and commercial applications resulting 
from that research." Instead, Mr. Capron said that he views 
himself as a roadblock to investigators, exerting caution. 
Moreover, he believes that the Subcommittee is fully qualified to 
provide expert advice on issues related to human gene therapy. 
For example, Mr. Capron stated that patients eligible for 
Dr. Anderson' protocol had received even more stringent 
protection from the scientists on the Human Gene Therapy 
Subcommittee than from the ethicists and lawyers. 
Dr. Epstein reiterated the Foundation's concern for protecting 
people who may be affected by gene therapy technology, and 
extended that concern by noting that all people can be affected 
by health care policy. He asked Mr. Rogers why the word 
"eugenics" had been used in the HEAC title when that is the most 
loaded term associated with human genetics. Mr. Rogers replied 
that it seemed to be the most accurate term. Dr. Epstein told 
him that the Subcommittee has gone on record as supporting 
somatic cell gene therapy, not germ line alterations as implied 
by "eugenics." 
Dr. McGarrity stated that because the target of this proposal is 
broader than NIH-supported research, perhaps this is not the 
proper forum for its consideration. Dr. Parkman emphasized that 
the use of gene therapy to treat a child with adenosine deaminase 
deficiency is quite a different issue from treatment to correct 
schizophrenia. 
Reflecting on the rather hostile reception to the Foundation's 
petition. Dr. Mahoney said that this Subcommittee had devoted a 
great deal of energy to accomplishing exactly what Mr. Rogers 
claims they are not adequately equipped to handle. Documentation 
of such inadequacy would be necessary to support the petition, in 
Dr. Mahoney's view. 
Dr. Anderson called attention to pages 201-204, a bibliography 
included as part of the proposed amendment to the Guidelines. 
When Mr. Rogers was unable to identify the origin of those 
references. Dr. Anderson replied that the bibliography was part 
of a preprint of a scientific paper that he had shared with 
Mr. Rif kin last month. Mr. Rogers apologized and agreed that 
this usage did constitute plagiarism. 
In closing. Dr. Walters noted that, in addition to Mr. Capron, 
Dr. Childress is also a member of the congressional Bioethics 
Advisory Committee, and that a Subcommittee liaison member. 
Dr. Robert Cook-Deegan, is its acting staff director. 
Dr. Walters informed Subcommittee members that they would receive 
2 items in their next mailing: (1) a report from the Reformed 
Church in America, "Genetic Engineering: Theological and Ethical 
Perspectives," and (2) a "Report on the Round Table Conference on 
Human Gene Therapy," from a September meeting of the National 
[318] Recombinant DNA Research, Volume 13 
